Recce Pharmaceuticals Doses Patients in Phase I/II Clinical

Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections

Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Sydney , New South Wales , Australia , United States , Jordyn Temperato , Andrew Geddes , Guillame Van Renterghem , James Graham , Lifesci Communications , Recce Pharmaceuticals Ltd , Recce Pharmaceuticals , Research Unit , Risk Foot Service , Pharmaceuticals Doses Patients , Diabetic Foot , South West Sydney Limb Preservation , Wound Research Unit , Liverpool Hospital , Pharmaceuticals Ltd , Liverpool Hospitals South West , Sydney Limb Preservation , Wound Research , Chief Executive Officer , High Risk Foot Service , Australia New Zealand Clinical Trial Registry , New Class , Synthetic Anti Infectives , Infectious Disease Product , Generating Antibiotic Initiatives Now , Fast Track Designation , Pew Charitable Trusts Global New Antibiotics , Development Pipeline , Investor Relations ,